Werewolf Therapeutics, Inc. — Form 8-K Summary
Reporting date: May 27, 2021, filed May 28, 2021. This current report concerns a board appointment and related compensation; it does not provide operating or financial results for a reporting period.
Business Context
Werewolf Therapeutics is a Delaware biotechnology company whose common stock trades on Nasdaq under the symbol HOWL. The company reported the appointment of Michael A. Sherman to its Board of Directors.
Board Appointment and Compensation
- Mr. Sherman was appointed as a Class I director, serving until the 2022 annual meeting or until his successor is elected and qualified.
- He was appointed chair of the Audit Committee.
- Mr. Sherman is chief executive officer of Chimerix, Inc. and previously served as chief executive officer, chief financial officer, and chief operating officer of Endocyte, Inc.
- Annual cash compensation will be $35,000 for board service and $15,000 for serving as Audit Committee chair, plus reimbursement of reasonable meeting-related expenses.
- He received an option to purchase 23,200 shares at an exercise price of $14.63 per share, equal to the company’s closing stock price on the appointment date.
- The option vests one-third on the first anniversary of the grant date and thereafter in equal monthly installments through the third anniversary, subject to continued board service.
- Mr. Sherman entered into the company’s standard form of indemnification agreement and is eligible for future annual director option grants.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity measures, or other operating financial metrics.
Material Changes, Outlook, and Risks
The material change reported is the addition of an experienced biopharmaceutical executive as a director and Audit Committee chair. The filing provides no management guidance, business outlook, contingencies, or new operating risk disclosures. The principal disclosed economic impact is the ongoing director cash compensation and equity-based compensation described above.
Investor Verification Items
- Confirm the vesting schedule, exercise price, and share count of the 23,200-share director option.
- Review the company’s non-employee director compensation program for eligibility for future grants.
- Review subsequent filings for any changes in Mr. Sherman’s board service, committee role, or compensation.
- Consult the company’s periodic reports for financial condition, liquidity, operating results, and biotechnology development risks, which are not included in this 8-K.